相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Incretins in obesity and diabetes
Chee W. Chia et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2020)
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
M. S. Capehorn et al.
DIABETES & METABOLISM (2020)
Modern pharmacological treatment of obese patients
Marcus May et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2020)
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
Tina K. Thethi et al.
DIABETES OBESITY & METABOLISM (2020)
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
Hellas Cena et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
Daisuke Yabe et al.
Lancet Diabetes & Endocrinology (2020)
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yuichiro Yamada et al.
Lancet Diabetes & Endocrinology (2020)
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams et al.
DIABETES THERAPY (2020)
GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
Matthew P. Gilbert et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Robert F. Kushner et al.
OBESITY (2020)
Prospective study of gut hormone and metabolic changes after laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass
Rachel Arakawa et al.
PLOS ONE (2020)
Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review
Stephen C. Bain et al.
DIABETES OBESITY & METABOLISM (2019)
The epidemiology of obesity
Yu Chung Chooi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy
Maria S. Svane et al.
GASTROENTEROLOGY (2019)
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard Pratley et al.
LANCET (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial
Alexander Dimitri Miras et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study
Juan J. Gorgojo-Martinez et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2019)
Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Michael A. Nauck et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care
Dominique Durrer Schutz et al.
OBESITY FACTS (2019)
Centrally Acting Agents for Obesity: Past, Present, and Future
Ann A. Coulter et al.
DRUGS (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial
Signe Frossing et al.
DIABETES OBESITY & METABOLISM (2018)
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
Karolin Bettge et al.
DIABETES OBESITY & METABOLISM (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines
Z. Dong et al.
OBESITY REVIEWS (2017)
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
Victoria Divino et al.
DIABETES THERAPY (2017)
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
Victoria Divino et al.
DIABETES THERAPY (2017)
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Blundell et al.
DIABETES OBESITY & METABOLISM (2017)
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
William M. Steinberg et al.
DIABETES CARE (2017)
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes
Heidi Storgaard et al.
DIABETES OBESITY & METABOLISM (2017)
Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
Hiep Nguyen et al.
ADVANCES IN THERAPY (2017)
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
A. Blackman et al.
INTERNATIONAL JOURNAL OF OBESITY (2016)
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events A Systematic Review and Meta-analysis
Rohan Khera et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Laurent Azoulay et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Laurent Azoulay et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
European Guidelines for Obesity Management in Adults
Volkan Yumuk et al.
OBESITY FACTS (2015)
Liraglutide and obesity: a review of the data so far
Ellen E. Ladenheim
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials
Fang Zhang et al.
JOURNAL OF DIABETES (2015)
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society
Michael D. Jensen et al.
CIRCULATION (2014)
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
Carol Wysham et al.
DIABETES CARE (2014)
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
J. van Can et al.
INTERNATIONAL JOURNAL OF OBESITY (2014)
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Kathleen M. Dungan et al.
LANCET (2014)
Differential Effects of Laparoscopic Sleeve Gastrectomy and Laparoscopic Gastric Bypass on Appetite, Circulating Acyl-ghrelin, Peptide YY3-36 and Active GLP-1 Levels in Non-diabetic Humans
Ahmed Yousseif et al.
OBESITY SURGERY (2014)
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type2Diabetes Inadequately Controlled on Metformin A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
Julio Rosenstock et al.
DIABETES CARE (2013)
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
T. A. Wadden et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse et al.
LANCET (2013)
Presence of Apolipoprotein C-III Defines a High Density Lipoprotein Subtype that is not Inversely Associated with Incident Coronary Events
Majken K. Jensen et al.
CIRCULATION (2013)
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A. Astrup et al.
INTERNATIONAL JOURNAL OF OBESITY (2012)
Hypogonadotropic Hypogonadism in Morbidly Obese Males Is Reversed After Bariatric Surgery
Silvia Pellitero et al.
OBESITY SURGERY (2012)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock et al.
LANCET (2009)
分享论文
